| Code | CSB-RA947666A0HU |
| Size | US$210 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
| Application | Recommended Dilution |
|---|---|
| WB | 1:500-1:5000 |
The delta-type opioid receptor (OPRD1) plays a central role in pain modulation, mood regulation, and reward pathways, making it a compelling target for neuroscience research focused on analgesia, addiction, and neuropsychiatric disorders. As one of the three classical opioid receptor subtypes, OPRD1 offers distinct pharmacological properties that continue to attract attention for therapeutic development, particularly for pain management strategies with reduced side effect profiles compared to mu-opioid receptor targeting.
This recombinant monoclonal antibody, clone 7G7, provides the reproducibility essential for longitudinal studies and multi-site collaborations. Because recombinant technology generates antibodies from defined sequences rather than traditional hybridoma methods, you can expect consistent performance across lots, eliminating the variability that can complicate data interpretation over extended research programs.
Validation by western blot demonstrates reliable detection across a broad panel of human cell lines, including the neuroblastoma line SH-SY5Y, which serves as a well-established neuronal model, as well as 293, HeLa, U251 glioblastoma, and A549 cells. Importantly, the antibody also detects OPRD1 in mouse brain tissue, confirming cross-species reactivity that supports translational studies moving between human cell-based systems and rodent models. The observed band at 41 kDa aligns precisely with the predicted molecular weight, indicating specific recognition of the target protein.
With validated performance in both ELISA and western blot applications at working dilutions from 1:500 to 1:5000, this antibody offers flexibility for expression profiling, receptor quantification, and pathway analysis in opioid signaling research.
There are currently no reviews for this product.